DORFSTRASSE 29, ZUG, V8
Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
MoonLake Immunotherapeutics Enters Underwriting Agreement for $75 Million Off...
Reports on Week 16 Results of the VELA Phase 3 Hidradenitis Suppurativa Program with the Nanobody® Sonelokimab
Reports Second Quarter 2025 Financial Results and Provides a Business Update
Submission of Matters to a Vote of Security Holders
Results of Operations and Financial Condition
FY 2024
Q3
Q2
Q1
FY 2023
FY 2023 amended
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Submission Upload
Correspondence